ReviewBritish journal of clinical pharmacology2026
Ocrelizumab-induced colitis: VigiBase disproportionality analysis, case reports and literature review.
Review in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsOcrelizumab is a humanized anti-CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab-induced colitis have been reported in the scientific literature.
methodsTo explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and disproportionality analysis of ocrelizumab-induced colitis registered in VigiBase, as well as an extensive literature review and a description of two cases from Luxembourg reported to our pharmacovigilance centre.
resultsOur VigiBase analysis revealed 400 cases of ocrelizumab-induced colitis, with 79.0% serious cases and a median time to onset of 17 months. The preferred term (PT) coded was 'colitis' (53.0%), followed by PTs related to inflammatory bowel diseases (33.5%). Significant disproportionality was found for high-level term 'colitis' and for 'colitis', 'colitis microscopic' and 'immune-mediated enterocolitis' PTs. Our literature review revealed 24 case reports corresponding to 36 patients with a median time to onset of 18 months and a predominance of unspecified colitis (61.1%) and inflammatory bowel diseases (27.8%). Two patients relapsed after ocrelizumab resumption.
conclusionsTogether, our findings of two relevant clinical cases of ocrelizumab-induced colitis, the literature review and the significant VigiBase disproportionality, suggest a potential safety signal for ocrelizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.